Incomplete Financial Disclosures: In the Letter to the Editor entitled “Reducing Opioid Abuse and Diversion,” published in the July 27, 2011, issue of JAMA (2011;306[4]:382), the financial disclosures were incomplete. They should have appeared as follows: Dr Fine reported receiving payment for serving on the advisory boards of Archimedes, Covidien, King (Pfizer), Meda, Purdue Pharma, Ameritox, Forest Labs, and Neuroadjuvants; providing medical legal consulting for Cephalon and Janssen; participating in CME activities for King (Pfizer), Endo, Pricara, and OrthoMcNeil; serving on speakers' bureaus for Pricara and OrthoMcNeil; receiving funds for research and writing assistance from Cephalon; being the president of the American Academy of Pain Medicine; being a board member of the American Pain Foundation (a nonprofit foundation that receives support from manufacturers of prescription opioids), being co-chair of the American Pain Society–American Academy of Pain Medicine Opioid Guideline panel, for which he received reimbursement for travel expenses; being chair of the National Initiative on Pain Control through the American Pain Foundation; being a strategic consultant for Capital Caring Hospice; serving as an expert witness for Cephalon; receiving grants from the National Institutes of Health; receiving book royalties from The Hospice Companion; having a 5% ownership in Asante medical education company; and being a board member of the Ossipee Lake Alliance. An accompanying letter appears in this issue of JAMA.